Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer
December 29, 2016 07:00 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Study is exploring potential benefits of...
Bavarian Nordic påbegynder forsøg med CV301 i kombination med nivolumab i patienter med lungekræft
December 29, 2016 07:00 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Forsøget evaluerer potentielle fordele ved at...
Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine
December 14, 2016 07:43 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
COPENHAGEN, Denmark, December 14, 2016 -...
Bavarian Nordic afslutter rekruttering til fase 2 forsøg med vaccine mod RS-virus
December 14, 2016 07:43 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KØBENHAVN, Danmark, 14. december 2016 -...
Bavarian Nordic iværksætter incitamentsprogrammer for ledelse og medarbejdere
December 08, 2016 09:01 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KØBENHAVN, Danmark, 8. december 2016 - Bavarian...
Bavarian Nordic Introduces New Incentive Programs for Executive Management and Employees
December 08, 2016 09:01 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
COPENHAGEN, Denmark, December 8, 2016 -...
Bavarian Nordic præsenterer på Citi 2016 Global Healthcare Conference
December 05, 2016 11:30 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KØBENHAVN, 5. december 2016 - Bavarian Nordic...
Bavarian Nordic to Present at Citi 2016 Global Healthcare Conference
December 05, 2016 11:30 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
COPENHAGEN, Denmark - December 5, 2016 -...
Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE® Smallpox Vaccine
November 23, 2016 09:22 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Second and final Phase 3 study to support...
Bavarian Nordic afslutter rekruttering til det sidste fase 3 forsøg med koppevaccinen IMVAMUNE®
November 23, 2016 09:22 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Forsøget er det andet og sidste fase 3 forsøg,...